| Old Articles: <Older 6771-6780 Newer> |
 |
Pharmaceutical Executive September 1, 2010 |
Tracking Meetings in Troubled Times Scrutiny of pharmaceutical promotion and gifts to practitioners has intensified, with more states enacting reporting requirements. What kind of impact is all this having on meetings and physician attendance?  |
Pharmaceutical Executive September 1, 2010 William Looney |
The Coming Second Act Reinvention takes more than a pithy redraft of the strategy plan or mission statement; money, a change in business culture, and the mindset of thousands of employees is required too.  |
Pharmaceutical Executive September 1, 2010 |
The Testing of the Tests FDA seeks to regulate genetic tests more actively, while encouraging diagnostic development.  |
The Motley Fool October 12, 2010 Seth Jayson |
Where Is PerkinElmer's Bottom Line Headed? Here's the current margin snapshot for PerkinElmer and some of its sector and industry peers and direct competitors.  |
The Motley Fool October 12, 2010 Brian Orelli |
This Drugmaker Stands on a Platform Above the Rest ImmunoGen signs up another partner.  |
The Motley Fool October 12, 2010 Travis Hoium |
Geron Shares Popped: What You Need to Know Geron shares jumped 10% after the company announced that its first patient has enrolled in the company's stem cell clinical trial.  |
The Motley Fool October 12, 2010 Travis Hoium |
King Pharmaceuticals Shares Popped: What You Need to Know King Pharmaceuticals shares are up nearly 40% today after it was announced the company would be purchased by Pfizer Inc.  |
The Motley Fool October 12, 2010 Brian Orelli |
Clinical Trial Positive! Shares Just Barely A story about expectations. Seattle Genetics is two for two in recent weeks.  |
The Motley Fool October 11, 2010 Brian Orelli |
FDA Rejection, but Still Jazzed Up Sometimes, biotechs are like that.  |
The Motley Fool October 11, 2010 Brian Orelli |
A Dendreon Killer? Not Yet. Johnson & Johnson's abiraterone looks good, but won't knock off the newcomer.  |
| <Older 6771-6780 Newer> Return to current articles. |